M.M. Ostrovskyy, M.O. Kulynych-Miskiv, I.O. Savelikhina

          Ivano-Frankivsk National Medical University, Department of Phthisiology and Pulmonology with the course of occupational diseases, Ivano-Frankivsk, Ukraine e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.



Abstract. The article contains literature review on the problems of treatment of chronic obstructive pulmonary disease. Recommendations "Global Strategy: diagnosis, treatment and prevention of COPD (GOLD), European Respiratory Society (ERS) and a protocol of care for diagnosis and treatment of COPD are presented. The importance of using modern technologies in the treatment of chronic obstructive pulmonary disease is highlighted. Inhalation therapy as one of the most commonly used methods of treatment for patients with bronco-obstructive pathology is used to create the necessary concentration of medicinal substance in a certain area of the respiratory tract, providing local activity of the drug, minimal accumulation of drugs in other organs and systems of the organism. In this way, maximum efficacy is achieved with minimal pharmacological costs and side effects, since it is precisely inhalation systems that provide the optimum opportunity for the delivery of therapeutic agents directly to the respiratory system of the patient. The world medical community, having analyzed the experience of the last decades, came to the conclusion that the main principles of treatment of patients with chronic obstructive pulmonary disease are the regularity and continuity of the basic therapy according to the severity of the disease; gradual increase in the intensity of treatment depending on the severity of the course of the disease; the variability of the individual selection of treatment programs, depending on the response to treatment, which is determined by careful monitoring of the clinical and functional features of the disease.

The rapid evolution of pulmonary pathology and the unstable development of the pharmacological industry make it necessary to further conduct modern research on the interaction of sanogenetic systems for the protection of the macro organism in conditions such as aggression of pathological exogenous and endogenous factors and adaptation to them. The present conditions put forward to the medical community (pulmonologists, therapists, family physicians, etc.) the task of using well-balanced, scientifically substantiated and consolidated programs for the diagnosis of COPD in the early stages, when the rate of progression of the disease is significantly reduced.

Due to the multi-vector of its influence on the various pathogenetic mechanisms of development of the pathological process, tiotropium bromide, being a means of basic therapy, is able to manifest itself not only as prolonged bronchodilator, but also to show other manifestations of its application.


Keywords: chronic obstructive pulmonary disease, treatment, tiotropium bromide.


Full text: PDF (Rus)

  1. Garcia-Aymerich J. Regular Physical Activity Modifies Smoking-related Lung Function Decline and Reduces Risk of Chronic Obstructive Pulmonary Disease / Judith Garcia-Aymerich, Peter Lange, Marta Benet, Peter Schnohr and Josep M. Antó // American Journal of Respiratory and Critical Care Medicine. – 2007. – Vol. 175. – Р. 458-463.
  2. Jones P.W. COPD assessment test --rationale, development, validation and performance / P.W. Jones // J. COPD. – 2013. – Vol.10. – № 2. – P. 269-271.
  3. Alagha K, Palot A, Sofalvi T, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5 (2):85–98.
  4. Decramer M. Clinical Trial Design Considerations in Assessing Long-Term Functional Impacts of Tiotropium in COPD^ The UPLIFT Trial / Mark Decramer, M. D. Bartolome Celli, Donald P. Tashkin, Romain A. Pauwels, Deborah Burkhart, Cara Cassino, and Steven Kesten // Eur Respir J April 2008. – Vol. 31. – Р. 742-750.
  5. Adeloye D, Chua S, Lee C, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415.
  6. Celli B. R. Effect of pharmacotherapy on rate of decline of lung function in COPD results from the TORCH study / B. R. Celli, N. E. Thomas, J. A. Anderson et al. // Am J Respir Crit Care Med. 2008 Aug 15. – Vol. 178, №4. – Р. 322-328.
  7. Celli B. Improvement in resting inspiratory capacity and hyperinflation with Tiotropium in COPD patients with increased static lung volumes / B. Celli, R. Wallack, S. Wang // Thorax. – 2003. – Vol.124. – P.1743-1748.
  8. Celli, B. Cardiovascular Safety of Tiotropium in Patients With COPD / B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, D. P. Tashkin // Chest. – 2010. – Vol. 137. – Р. 20-30.
  9. Celli B.R. Exacerbations of chronic obstructive pulmonary disease / B.R. Celli, P.J. Barnes //Eur. Respir. J.– 2007. – Vol.29. – p. 1224-1238.
  10. Cazzola, M. From large clinical trials to management of COPD in the real world / M. Cazzola // Ther Adv Respir Dis. – 2009. – Vol.3. – Р. 39-46.
  11. Casarosa, P. Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs / P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, M. Pieper // J. Pharmacol. Exp. Ther. – 2009. Vol. 330. – Р. 660-668.
  12. Rice KL, Leimer I, Kesten S, Niewoehner DE. Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Transl Res. 2008; 152(2):88–94.
  13. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD / V. Brusasco // Eur. Respir. Rev., December 1, 2006. – Vol. 15, №99. – Р. 32 – 36.
  14. Barr R. G. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis / R. G. Barr, J. Bourbeau, C. A .Camargo, and F. S. F. Ram // Thorax, October 1, 2006. – Vol. 61, №10. – Р. 854 – 862.
  15. Barnes P. J. Chronic obstructive pulmonary disease: molecular and cellular mechanisms / P. J. Barnes, S. D. Shapiro, R. A. Pauwels // Eur Respir J. – 2003. – Vol. 22. – Р. 672–688.
  16. Barnes P. J. The role of anticholinergics in COPD / P. J. Barnes // Am J Med. – 2004. – 117: suppl. 12A, P.24-32.
  17. Barnes P. J. Future treatments for chronic obstructive pulmonary disease and its comorbidities / P. J. Barnes // Proc Am Thorac Soc. – 2008. – Vol. 5. – Р.857–864.
  18. Barnes J. Peter. Distribution of Receptor Targets in the Lung / J. Peter Barnes // The Proceedings of the American Thoracic Society. – 2004. – №1. – Р.345-351.
  19. Anzueto, A. Efficacy of tiotropium in the prevention of exacerbations of COPD / A. Anzueto, M. Miravitlles // Ther Adv Respir Dis. – 2009. – Vol. 3. – Р. 103-111.
  20. Aaron S. D. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of COPD: a randomized trial / S. D. Aaron, K.L. Vandemheen, D. Fergusson, [et al] // Ann Intern Med. – 2007. – Vol.146. – P.545-555.
  21. Kistemaker LE, van Os RP, Dethmers-Ausema A, et al. Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2015;308(1):L96–L103.
  22. Feschenko Iu. I. Veduschie spetsyalisty proanalizirovali tekuschee sostoianie problemy KhOZL v Ukraine i nametili puti ee reshenia [Тekst] / Iu.I. Feschenko, L. А. Iashyna // Zdorovia Ukrainy — hruden 2010 — №24 (253) — С. 31 — 33.
  23. Ovcharenko S.I. Evoliutsia hlobalnoy initsiativy po khronicheskoy obstruktivnoy bolezni liohkikh i novy podkhod k protivovospalitelnoy terapii / S.I. Ovcharenko, Ia.К. Haletskayte // Lechaschiy vrach. — 2014. — №1.">URL:
  24. Ostrovsky М. М. Khronichne obstruktyvne zakhvoriuvannia lehen: novi vidtinky problemy / М. М. Ostrovsky // Astma і alerhia. – 2016. – №4. – С. 52-54.
  25. Feschenko Iu. І. Osnovy inhaliatsiynoi terapii pry khronochnomu obstruktyvnomu zakhvoriuvanni lehen ta bronkhialniy astmi / Iu. І. Feschenko, Т.О. Pertseva, L. І. Konopkina. – К.2005. – 72с.
  26. Feschenko, Iu. I. Kontrol nad KHOZL – vozmozhen li on sehodnia? Iu.I. Feschenko, L.А. Iashyna, Т.А. Pertseva // Zdorovia Ukrainy. — hruden 2010 — №1 (13). — С. 10 — 11.
  27. Feschenko Iu.І. Khronichne obstruktyvne zakhvoriuvannia lehen: etiolohia, patohenez, klasyfikatsia, diahnostyka, terapia (proekt natsionalnoi uhody): materialy zizdu. Iu. І. Feschenko, L.О. Iashyna, О.Ia. Dziublyk [ta іnshі] // Ukrainsky pulmonolohichny zhurnal. — 2013. — №3. — Dodatok. — С. 7—12.
  28. Nakaz МОZ Ukrainy №555 vid 27.06.2013 "Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnomu obstruktyvnomu zakhvoriuvanni lehen ".
  29. Ostrovskiy N. N. Rezultaty UPLIFT – novye vozmozhnosti v lechenii khronicheskikh obstruktivnykh zabolevaniy lehkikh / N.N. Ostrovskiy, L.А. Iashyna, Iu.I. Feschenko // Zdorovia Ukrainy. – 2009, hruden. – №24. – С.30-31.
  30. Pertseva Т. О. Preimuschestva ranneho i dlitelnoho lechenia KhOZL s primeneniem tiotropia / Т. О. Pertseva // Zdorovia Ukrainy. – 2009, liuty. – №2/1. – С.8.
  31. Porivnialni dani pro rozpovsiudzhenist khvorob orhaniv dykhannia і medychnu dopomohu khvorym na khvoroby pulmonolohichnoho ta alerhichnoho profiliu v Ukraini za 2001-2005 rr. / АМN Ukrainy. Tsentr medychnoi statystyky. Іn-t ftyziatrii і pulmonolohii іm. F.H.Ianovskoho. – К., 2006. – 45 с.
  32. Rezoliutsia IV zizdu ftyziatriv і pulmonolohiv Ukrainy [Тekst]: informatsiyny lyst / Instytut ftyziatrii ta pulmonolohii іm. F.H.Ianovskoho АМN Ukrainy. – Кyiv, 2008. – 2 с. [Rezoliutsia]
  33. Spiriva v lechenii KhOZL: novye dokazatelstva effektivnosti i bezopasnosti premenenia po rezultatam issledovania UPLIFT / Iu.I. Feschenko, L. А. Iashyna // [Materialy pres-konferentsii po problemakh diahnostyky і likuvannia khronichnoho obstruktyvnoho zakhvoriuvannia lehen (KhOZL) u sviti ta v Ukraini] Zdorovia Ukrainy. – 2008, zhovten. – №20. – С.11.
  34. Merkulova О. Obstruktyvni zakhvoriuvannia lehen: realii klinichnoi praktyky // Zdorovia Ukrainy. – № 2 (39). – 2017. – С. 34-36.
  35. Gosens R. Muscarin receptor signaling in the pathophysioligy of asthma and COPD / R. Gosens, J. Zaagsma, H. Meurs, [et al ] // Respir Ses. – 2006. – Vol.7. – P.73.
  36. Gosens R. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling / R. Gosens, I. S. Bos, J. Zaagsma, H. Meurs // Am J Respir Crit Care Med 2005. –-  №171. –  Р. 1096-1102.
  37. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2017. Available from:
  38. Gross N. J. Tiotropium Bromide / N. J. Gross // Chest, December 1, 2004. – Vol. 126, №6. – Р. 1946 – 1953.
  39. Keene, O. N. Lung function decline in COPD trials / O. N. Keene, B. Celli, J. A. Anderson, G. T. Ferguson, C. R. Jenkins, P. W. Jones, J. Vestbo, K. Knobil, J. C. Yates, P. M. A. Calverley // Eur Respir J. – 2009. – Vol.33. – Р. 708-709.
  40. MacNee W. Pathogenesis of Chronic Obstructive Pulmonary Disease / W. MacNee // Proceedings of the ATS, November 1, 2005. – Vol. 2, №4. – Р. 258-266.
  41. Matthiesen S. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation / S. Matthiesen, A. Bahulayan, S. Kempkens [et al.] // Am J Respir Cell Mol Biol. – 2006. – Vol. 35. – Р. 621–627.
  42. Miravitlles M. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies / M. Miravitlles, A. Anzueto // International Journal of COPD. – 2009. – Vol. 4. – Р.192-193.
  43. Racke K. Control by cholinergic mechanisms / K. Racke, U. R. Juergens, S. Matthiesen // Eur J Pharmacol. – 2006. – Vol.533. – P.57-68.
  44. Soriano J. B. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice / J. B. Soriano, J. Vestbo, N. B. Pride, V. Kiri, C. Maden, W. C. Maier // Eur Respir J. – 2002. -–Vol.20. – Р. 819–825.
  45. Pertseva T. Influence of tiotropium bromide (TB) on mucociliary clearance (MCC) in patients with COPD / T. Pertseva, O. Lykholat, O. Gurzhiy // Abstract presented at European Respiratory Society (ERS) annual meeting, Vienna, Austria. 12-15 September, 2009.
  46. Pieper M. P. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide / M. P. Pieper, N. I.Chaudhary, J. E. Park // Life Sci. 2007 May 30. – Vol. 80, №24-25, Р. 2270-2273.
  47. Powrie D. I. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD / D. I. Powrie, T. M. Wilkinson, G.C. Ponaldson [et al.] // Eur Respir J 2007. – Vol. 30. – Р. 472-478.
  48. Tashkin Donald. Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses / Donald Tashkin, MD, FCCP and Steven Kesten, MD, FCCP // CHEST May 2003. – Vol. 123, № 5. – Р. 1441-1449.
  49. Vincken W. Bronchodilator treatment of stable COPD: long-acting anticholinergics / W. Vincken // Eur. Respir. Rev., September 1, 2005. – Vol. 14, №94. – Р. 23-31.
  50. Zaagsma J. Remodelling and inflammation in a guinea pig model of COPD: effects of tiotropium / J. Zaagsma, T. Pera, A. B. Zuidhof, R. Gosens, H. Maarsingh, H. Meurs // Abstract presented at European Respiratory Society (ERS) annual meeting, Vienna, Austria. 12-15 September, 2009.